Loading…

Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor

The present study describes the cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV protease inhibitor currently in phase III clinical trials. BI 201335 showed a good Caco-II permeability (8.7 × 10−6 cm/sec) and in vitro metabolic stability (predicted h...

Full description

Saved in:
Bibliographic Details
Published in:Xenobiotica 2012-02, Vol.42 (2), p.164-172
Main Authors: Duan, Jianmin, Yong, Chan-Loi, Garneau, Michel, Amad, Ma'an, Bolger, Gordon, De Marte, Josie, Montpetit, Hélène, Otis, Francois, Jutras, Martin, Rhéaume, Manon, White, Peter W., Llinàs-Brunet, Montse, Bethell, Richard C., Cordingley, Michael G.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present study describes the cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV protease inhibitor currently in phase III clinical trials. BI 201335 showed a good Caco-II permeability (8.7 × 10−6 cm/sec) and in vitro metabolic stability (predicted hepatic clearence (CLhep)
ISSN:0049-8254
1366-5928
DOI:10.3109/00498254.2011.611546